Completed PHASE2 INTERVENTIONAL 2-arm NCT01025284

A Study for Participants With Small-Cell Lung Cancer

A Phase 2 Study of LY2523355 in Patients With Extensive-Stage Small-Cell Lung Cancer

Sponsor: Eli Lilly and Company

Interventions Granulocyte colony-stimulating factor (G-CSF) LY2523355

Updated 9 times since 2017 Last updated: Sep 9, 2019 Started: Dec 31, 2009 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 9 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Oct 2019 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Dec 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Athens, United States , Bucharest, Romania , Charleston, United States , Cherry Hill, United States , Cluj-Napoca, Romania , Marietta, United States , Memphis, United States , Scarborough, United States , Seoul, South Korea and 1 more location